Lymphoma Survivor Gives Birth 5 Years After Treatment
the Cancer Therapy Advisor take:
Fertility after cancer treatment is a concern for many patients. For some women, it can lead to infertility or early menopause. In this article, one patient shares the concerns she experienced while receiving cancer therapy in addition to the positive outcome. Molly Allen was already a mother of four when she was diagnosed with large B-cell non-Hodgkin lymphoma. She underwent chemotherapy at a hospital close to home but then made the decision to initiate proton therapy treatment at MD Anderson Cancer Center. After treatment, her doctors informed her that she likely would not be able to have any more children. At that time, she began to consider adoption. However, 5 years after receiving treatment and 9 years after receiving her lymphoma diagnosis, doctors discovered that she was pregnant during a routine PET scan at MD Anderson. The pregnancy proved to be more difficult than her previous ones, but there were not any major problems, and she gave birth to a healthy baby boy, which she described as “miraculous.” Although receiving the lymphoma diagnosis and undergoing treatment were difficult, Allen said that her family is stronger now. Although Chemotherapy Advisor normally reports only on clinical news, sharing patient experiences such as the one described in this article can be useful and provide insight into the patient experience.
Lymphoma survivor becomes mother again five years after cancer treatment
At 44 years old—5 years after successful treatment for large b-cell non-Hodgkin's lymphoma—Molly Allen gave birth to her fifth child, a son named Max. "After my lymphoma treatment, the doctors warned me I probably wouldn't be able to get pregnant, but I felt like we were meant to have another child," she says.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer